Abbott announces new structure for its Ludwigshafen, Germany, operations
Following the completion of its acquisition of BASF's pharmaceutical business, which includes the global operations of Knoll, Abbott Laboratories has proposed a new organizational structure for the Knoll operations in Germany. Under the proposal, Knoll AG will become Knoll GmbH. Abbott, as the new shareholder, will execute the transformation shortly following the close.
Knoll GmbH will be led by a three-person board of directors. Dr. Dieter Wagner, currently chairman of Knoll AG, will serve as chairman of Knoll GmbH.
Dr. Heinz Kipper, General Manager, Abbott Germany, will represent Commercial Operations on the Knoll GmbH board, in addition to maintaining his current responsibilities for Abbott Germany. Dr. Steffen Roellinger, head of the BASF Pharma R&D group "Systems, Processes and Support," will represent Research and Development on the Knoll GmbH board.
In addition, as part of the Abbott International Division, Dr. Wagner will serve as divisional vice president, German Operations, Ludwigshafen, and report to William G. Dempsey, senior vice president, International Operations. Dempsey will be nominated as chairman of the supervisory board of Knoll GmbH.
Dr. Kipper will remain general manager of Abbott Germany, Wiesbaden. Thomas Schätzle, General Manager of BASF Pharma's German sales organization Knoll Deutschland GmbH, will report to Dr. Kipper.
Knoll AG board members Hans-Carsten Hansen and Harald Huhn will assume new responsibilities at BASF Aktiengesellschaft.
Other news from the department business & finance
